AstraZeneca PLC (AZN)vsGeneDx Holdings Corp. (WGS)
AZN
AstraZeneca PLC
$161.07
+0.88%
HEALTHCARE · Cap: $263.09B
WGS
GeneDx Holdings Corp.
$77.08
+10.76%
HEALTHCARE · Cap: $1.93B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 13762% more annual revenue ($61.37B vs $442.68M). AZN leads profitability with a 17.0% profit margin vs -17.6%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
WGS
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.9%
Fair Value
$196.93
Current Price
$161.07
$35.86 discount
Intrinsic value data unavailable for WGS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
17.4% revenue growth
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Trading at 9.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -30.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : WGS
The strongest argument for WGS centers on Revenue Growth. Revenue growth of 17.4% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : WGS
The primary concerns for WGS are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while WGS is a growth play — different risk/reward profiles.
WGS carries more volatility with a beta of 1.91 — expect wider price swings.
WGS is growing revenue faster at 17.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 27/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
GeneDx Holdings Corp.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Sema4 Holdings Corp. The company is headquartered in Stamford, Connecticut.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?